Study Evaluating Pyrotinib in Combination With Capecitabine In Patients With HER2 Positive Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: pyrotinib combined with capecitabine
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Collaborators: Cancer Institute and Hospital, Chinese Academy of Medical Sciences